[{"uuid": "8e3a8ddf-037b-3692-a435-29d74e7fcbfe", "title": "CD70 Targeting Therapies Clinical Trials Insight 2025: 20+ CD70 Targeting Therapies In Clinical Trials", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cd70-targeting-therapies-clinical-trials-100000920.html", "providerPublishTime": 1738317600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/HP.E8HUfnyGeLtMAKwLgAQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc", "width": 480, "height": 58, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/KPtVInxraKsLNBMRw1U5aw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "038178be-7f72-3eb2-81bb-108b3b3dd0bc", "title": "The best shows on Amazon Prime Video right now (February 2025)", "publisher": "Digital Trends", "link": "https://finance.yahoo.com/m/038178be-7f72-3eb2-81bb-108b3b3dd0bc/the-best-shows-on-amazon.html", "providerPublishTime": 1738285289, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.9s55GLEgt43Yjw0T7V8Qw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/digital_trends_973/01bb8632146cd0c314db635fd41e1b87", "width": 1280, "height": 720, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/kV9JLx0KcNR9CyHpk7HFVA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/digital_trends_973/01bb8632146cd0c314db635fd41e1b87", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "335d0b5f-cf32-3521-aa0b-e69189d33f91", "title": "FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/fda-clears-allogenes-ind-car-163400440.html", "providerPublishTime": 1738168440, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/QSgbLgHaS28STBWt5rEywQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ALLO"]}, {"uuid": "3a148d78-cef3-3949-8270-0e27b5acede6", "title": "Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/allogene-therapeutics-announces-benjamin-m-133000440.html", "providerPublishTime": 1738157400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/BgNVN1GbL6VlVEp8_gLLjQ--~B/aD0yODMyO3c9MzM4MTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/b6e9e018fa475ee63e7d8caf0e38d645", "width": 3381, "height": 2832, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/BatG9ehqKYcS8R3Bpf_bOg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b6e9e018fa475ee63e7d8caf0e38d645", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ALLO"]}, {"uuid": "827f21e4-ae4d-3983-89e7-169e4f385259", "title": "Allogene Therapeutics Cleared to Start Phase 1 Testing of ALLO-329 Drug Candidate", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/allogene-therapeutics-cleared-start-phase-155429612.html", "providerPublishTime": 1738079669, "type": "STORY", "relatedTickers": ["ALLO"]}, {"uuid": "b295e035-8238-3170-b55e-987cad455884", "title": "Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/allogene-therapeutics-secures-u-fda-133000401.html", "providerPublishTime": 1738071000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/42ZOusfrZhV3i6.xrLIzhQ--~B/aD05NDY7dz0yMjU3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/70b24ee6cd65fa29c05e47e1fea9bc9a", "width": 2257, "height": 946, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/9QGktghblQNE3o5yp84JSg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/70b24ee6cd65fa29c05e47e1fea9bc9a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ALLO"]}, {"uuid": "6a0ffff0-9e8b-3f48-881b-ed14ed549734", "title": "UNESCO Intangible Cultural Heritage Spring Festival Debuts in Greece, Presented by Beijing Municipal Culture and Tourism Bureau", "publisher": "Newsfile", "link": "https://finance.yahoo.com/news/unesco-intangible-cultural-heritage-spring-050900685.html", "providerPublishTime": 1737954540, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/hPxNLdvPJgXwtn.CtivOaQ--~B/aD0zMDI7dz01NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/86a9e8a35c398b9a7307770d367927aa", "width": 550, "height": 302, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/OhQPpQDNB6AojAz1FYUOdA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/newsfile_64/86a9e8a35c398b9a7307770d367927aa", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "afdc8830-b19b-3016-a10b-f9057c59531d", "title": "MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/mink-therapeutics-targets-immune-reconstitution-191300908.html", "providerPublishTime": 1737659580, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/67DNPZ3DVCfNrGE_4VuXNQ--~B/aD00NDU7dz0xMTQ3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/53e4d7bc9eb5541f290a89d3901392ed", "width": 1147, "height": 445, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/c784t92326t2hS5nC6SA.Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/53e4d7bc9eb5541f290a89d3901392ed", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["INKT"]}, {"uuid": "d67dedc3-541a-356d-8491-4174763ced5c", "title": "Intelerad Expands AI Ecosystem with CARPL.ai Partnership", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/intelerad-expands-ai-ecosystem-carpl-140000133.html", "providerPublishTime": 1737554400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/xEaR3Yb2aAiuMnc2dwemEA--~B/aD0xNzg2O3c9MzQwNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5d5748149643b64fa21e4a7efdeed7a6", "width": 3406, "height": 1786, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/FtHv8PS0GFPKZY6FEKwHmA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/5d5748149643b64fa21e4a7efdeed7a6", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "7a9b4079-fe40-3b4b-ad4f-6618e6a7ed83", "title": "MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/maat-pharma-announces-positive-second-170000072.html", "providerPublishTime": 1737478800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/RrGqb7pgx.8rjQtAJKFn6A--~B/aD00ODA7dz00NDI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/886511a4d1b8864546d58008822ed101", "width": 442, "height": 480, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/z9osAlXaFginC_fGhe6sxA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/886511a4d1b8864546d58008822ed101", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["MAAT.PA"]}, {"uuid": "43c03212-67f6-3634-bb0a-16f85b56c1a5", "title": "Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/century-therapeutics-announces-investigator-initiated-120000642.html", "providerPublishTime": 1737460800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/97dqWeswHs8cfp6vbFoonQ--~B/aD00MjI7dz0xNDE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/1e32bfaefbccf3446e603039ed3861b6", "width": 1417, "height": 422, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/mQ.ddy.m4KD7VMcjIn1_0w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/1e32bfaefbccf3446e603039ed3861b6", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["IPSC"]}, {"uuid": "959af9be-5b02-358e-9602-3fea68296a1c", "title": "WeBank Technology Services Embarks on Global Expansion, Bringing Expertise in FinTech to New Markets", "publisher": "PR Newswire", "link": "https://finance.yahoo.com/news/webank-technology-services-embarks-global-083400002.html", "providerPublishTime": 1737362040, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/d8ikMR9nA5XbzW5aAgkzCQ--~B/aD0yNjc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9a04b1314f52d9562f464eb635c3e6b0", "width": 400, "height": 267, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/4lnsutRGFdfCvlbBIj.I.A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/9a04b1314f52d9562f464eb635c3e6b0", "width": 140, "height": 140, "tag": "140x140"}]}}]